Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy

Immunogenicity, Effectiveness, and Safety of Trivalent Inactivated Influenza Split Vaccine in Patients with Inflammatory Joint Diseases Receiving Modern Antirheumatic Therapy

According to the currently available data from large cohort studies, patients with immuno-inflammatory rheumatic diseases (IIRDs) are at increased risk of infectious complications, including influenza, compared to the general population. Vaccinations are a critical component of their care. However,...

Bibliografski detalji
Glavni autori:	M. M. Baranova, N. V. Muravyeva, B. S. Belov, M. E. Diatroptov, D. V. Bukhanova
Format:	Članak
Jezik:	Russian
Izdano:	LLC "Publishing House OKI" 2024-06-01
Serija:	Антибиотики и Химиотерапия
Teme:	influenza rheumatoid arthritis ankylosing spondylitis psoriatic arthritis vaccination efficacy immunogenicity safety
Online pristup:	https://www.antibiotics-chemotherapy.ru/jour/article/view/1129

Slični predmeti

Immunogenicity, efficacy and safety of the three-valent inactivated influenza split vaccine in patients with ankylosing spondylitis and psoriatic arthritis
od: M. M. Baranova, i dr.
Izdano: (2024-06-01)

Efficacy, safety and immunogenicity of a trivalent inactivated split influenza vaccine in patients with rheumatic diseases
od: D. V. Bukhanova, i dr.
Izdano: (2018-07-01)

Do individuals with inflammatory arthritis receive minimally adequate treatment for incident depression and anxiety: A population-based study
od: Alyssa Howren, i dr.
Izdano: (2025-01-01)

Gait characteristics associated with the foot and ankle in inflammatory arthritis: a systematic review and meta‐analysis
od: Matthew Carroll, i dr.
Izdano: (2015-01-01)

Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
od: Svedbom A, i dr.
Izdano: (2017-01-01)

Rheumatoid arthritis and spondyloarthritis prevalence in four European countries - a comparative study
od: Zlatković-Švenda Mirjana, i dr.
Izdano: (2022-01-01)

Association Between Nursing Support Levels and Effectiveness of Golimumab in the Management of Patients with Rheumatologic Diseases
od: Hermine Leroi, i dr.
Izdano: (2020-05-01)

Comorbidities in inflammatory joint and spine diseases in XXI century
od: I Z Gaydukova, i dr.
Izdano: (2018-12-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
od: Takacs P, i dr.
Izdano: (2019-01-01)

Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
od: Joshua L. Lee, i dr.
Izdano: (2018-08-01)

The frequency and structure of comorbid infections in patients with spondyloarthritis (preliminary own data)
od: M. M. Baranova, i dr.
Izdano: (2021-03-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
od: M. Rossini, i dr.
Izdano: (2015-03-01)

Hypogonadism in men with inflammatory joint diseases: Frequency and clinical characteristics
od: Taras S. Panevin, i dr.
Izdano: (2024-06-01)

The data project: a shared approach between stakeholders of the healthcare system in definition of a therapeutic algorithm for inflammatory arthritis
od: I. Pantano, i dr.
Izdano: (2023-03-01)

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis
od: Milena Iwaszko, i dr.
Izdano: (2021-11-01)

Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
od: Viola Sacchi, i dr.
Izdano: (2010-06-01)

Circulating miRNA Correlates with Lipid Profile and Disease Activity in Psoriatic Arthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis Patients
od: Krzysztof Bonek, i dr.
Izdano: (2022-04-01)

Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
od: Santhi Mantravadi, i dr.
Izdano: (2020-09-01)

Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
od: Philip Brenner, i dr.
Izdano: (2020-02-01)

Evaluation of the possibility of axial psoriatic arthritis patients meet classification criteria for axial spondyloarthritis and ankylosing spondylitis
od: E. E. Gubar, i dr.
Izdano: (2023-08-01)

Nod-like receptors in inflammatory arthritis
od: Sahib Singh Madahar, i dr.
Izdano: (2024-02-01)

Inflammatory arthritis and eye diseases: a Mendelian randomization study
od: Xinlin Nie, i dr.
Izdano: (2023-10-01)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
od: M. Elaine Husni, i dr.
Izdano: (2022-03-01)

A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study
od: Christian Dejaco, i dr.
Izdano: (2022-06-01)

SAFETY AND EFFECTIVENESS OF TRI VALENT INACTIVATED SPLIT VIRION INFLUENZA VACCINE IN PATIENTS WITH RHEUMATOID DISORD ERS
od: D. V. Bukhanova, i dr.
Izdano: (2018-07-01)

The association of relapsing polychondritis and spondylarthritis – three case reports
od: Eleonora Alina Dragomir-Lica, i dr.
Izdano: (2023-09-01)

Characteristics of patients with psoriatic arthritis in Korea: focusing on axial involvement
od: Hanna Park, i dr.
Izdano: (2024-01-01)

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
od: Acar M, i dr.
Izdano: (2018-11-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
od: Yu. V. Muravyev, i dr.
Izdano: (2020-05-01)

Adherence to biological therapies in patients with chronic inflammatory arthropathies
od: Noemí Martínez-López de Castro, i dr.
Izdano: (2019-07-01)

Unraveling immune cell heterogeneity in autoimmune arthritis: insights from single-cell RNA sequencing
od: Sotaro Nakajima, i dr.
Izdano: (2024-10-01)

Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents
od: Andrea Picchianti-Diamanti, i dr.
Izdano: (2025-02-01)

The troubling liaison between cancer and metabolic syndrome in chronic inflammatory rheumatic diseases
od: Giovanni Cioffi, i dr.
Izdano: (2021-03-01)

Diagnosis of spondyloarthritis: should we need new criteria?
od: I. Z. Gaidukova, i dr.
Izdano: (2015-03-01)

Prevalence of spondyloarthritis and its subtypes - are they really comparable?
od: Zlatković-Švenda Mirjana I., i dr.
Izdano: (2019-01-01)

Significance of asymptomatic hyperuricemia in ankylosing spondylitis
od: R. M. Balabanova, i dr.
Izdano: (2021-06-01)

Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study
od: Muhammad Haroon, i dr.
Izdano: (2018-04-01)

Newly diagnosed seropositive rheumatoid arthritis in a 52-year-old man superimposed on long-standing ankylosing spondylitis during secukinumab treatment
od: Jaroslaw Nowakowski, i dr.
Izdano: (2023-10-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
od: Tacjana Anna Barczyńska, i dr.
Izdano: (2015-12-01)

Features of medical and social expertise in ankylosing spondylitis and psoriatic arthritis
od: T. V. Dubinina, i dr.
Izdano: (2023-02-01)